WO2011041609A3 - Formulations topiques - Google Patents

Formulations topiques Download PDF

Info

Publication number
WO2011041609A3
WO2011041609A3 PCT/US2010/051001 US2010051001W WO2011041609A3 WO 2011041609 A3 WO2011041609 A3 WO 2011041609A3 US 2010051001 W US2010051001 W US 2010051001W WO 2011041609 A3 WO2011041609 A3 WO 2011041609A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
topical formulations
provides
pain
Prior art date
Application number
PCT/US2010/051001
Other languages
English (en)
Other versions
WO2011041609A2 (fr
Inventor
Servet Buyuktimkin
Nadir Buyuktimkin
Jagat Singh
John M. Newsam
Dominic King-Smith
Edward T. Kisak
Bradley S. Galer
Original Assignee
Nuvo Research Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvo Research Inc. filed Critical Nuvo Research Inc.
Priority to EP10762838A priority Critical patent/EP2482850A2/fr
Publication of WO2011041609A2 publication Critical patent/WO2011041609A2/fr
Publication of WO2011041609A3 publication Critical patent/WO2011041609A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques topiques, des méthodes de préparation, et des méthodes de traitement mettant en œuvre un inhibiteur sélectif de COX-2 utile pour le traitement de la douleur, en particulier la douleur associée à l'arthrose. Les compositions de l'invention offrent une bonne perméabilité et biodisponibilité sur le site cible. Dans certains modes de réalisation préférés, on décrit une composition comprenant étoricoxib, 2-amino-2-méthylpropanol (AMP), un épaississant cellulosique, et de l'urée.
PCT/US2010/051001 2009-09-30 2010-09-30 Formulations topiques WO2011041609A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10762838A EP2482850A2 (fr) 2009-09-30 2010-09-30 Formulations topiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24722209P 2009-09-30 2009-09-30
US61/247,222 2009-09-30

Publications (2)

Publication Number Publication Date
WO2011041609A2 WO2011041609A2 (fr) 2011-04-07
WO2011041609A3 true WO2011041609A3 (fr) 2011-05-26

Family

ID=43618884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051001 WO2011041609A2 (fr) 2009-09-30 2010-09-30 Formulations topiques

Country Status (2)

Country Link
EP (1) EP2482850A2 (fr)
WO (1) WO2011041609A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2575813A1 (fr) * 2010-05-28 2013-04-10 Nuvo Research Inc. Formulation topique d'étoricoxib
US9144553B2 (en) 2012-12-21 2015-09-29 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
CA2972065A1 (fr) 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Methodes et formulations pour l'administration transdermique
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096435A2 (fr) * 2001-05-31 2002-12-05 Pharmacia Corporation Composition d'inhibiteur selectif de cyclooxygenase-2, permeable a la peau
WO2004047816A1 (fr) * 2002-11-21 2004-06-10 Pharmacia Corporation Timbre transdermique inhibant de façon selective la cyclooxygenase-2
US20050096371A1 (en) * 2003-11-05 2005-05-05 Anandi Krishnan Topical pharmaceutical compositions
WO2008049020A2 (fr) * 2006-10-17 2008-04-24 Nuvo Research Gel de diclofénac

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096435A2 (fr) * 2001-05-31 2002-12-05 Pharmacia Corporation Composition d'inhibiteur selectif de cyclooxygenase-2, permeable a la peau
WO2004047816A1 (fr) * 2002-11-21 2004-06-10 Pharmacia Corporation Timbre transdermique inhibant de façon selective la cyclooxygenase-2
US20050096371A1 (en) * 2003-11-05 2005-05-05 Anandi Krishnan Topical pharmaceutical compositions
WO2008049020A2 (fr) * 2006-10-17 2008-04-24 Nuvo Research Gel de diclofénac

Also Published As

Publication number Publication date
EP2482850A2 (fr) 2012-08-08
WO2011041609A2 (fr) 2011-04-07

Similar Documents

Publication Publication Date Title
WO2008132229A3 (fr) Solutions et compositions hautement concentrées en insuline
WO2008049020A3 (fr) Gel de diclofénac
MX277822B (es) Derivados de urea de tropano, su preparacion y su aplicacion terapeutica.
WO2011032169A3 (fr) Compositions et formulations pharmaceutiques comprenant des inhibiteurs du domaine d'homologie à la pleckstrine et leurs méthodes d'utilisation
ZA200809356B (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
WO2012021715A3 (fr) Formulations stables de linaclotide
EP2431366A4 (fr) Nouveau composé conjugué de chlore e6-acide folique, procédé de préparation de ce composé et composition pharmaceutique contenant ledit composé pour le traitement du cancer
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
IL223463A (en) Urea History, Pharmaceutical Preparations Containing and Uses
WO2011113060A3 (fr) Composés antiviraux et procédés d'utilisation de ceux-ci
IL209593A (en) Diamino-Pyridine, Pyrimidine and Pyridazine Derivatives, Pharmaceutical Preparations Containing Them and Uses as Modulators of Histamine H4 Receptor
EP2152279A4 (fr) Utilisation d'un tensioactif biologique en tant qu'agent anti-inflammatoire et solution de conservation de tissus
WO2010021607A3 (fr) Préparation pharmaceutique
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
WO2011060195A3 (fr) Formulation eutectique topique
EP2241569A4 (fr) Composés de thiénopyridazine, leurs préparations, compositions pharmaceutiques et utilisations
WO2009094457A3 (fr) Benzhydryléthers substitués
WO2011103018A8 (fr) Dérivés d'imidazole fusionnés et substitués, compositions pharmaceutiques et procédés d'utilisation associés
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
WO2011041609A3 (fr) Formulations topiques
FR2941952B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011107866A3 (fr) Dérivés silyliques de polysaccharides
WO2011139249A3 (fr) Composition pharmaceutique renfermant du cefdinir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762838

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010762838

Country of ref document: EP